Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability
Whether the dose of B6 included in a compounded semaglutide formulation is sufficient to meaningfully address fatigue is unclear, but the theoretical basis is reasonable
Copper deficiency presents with anemia, leukopenia, muscle weakness, fatigue, altered pigmentation of both skin and hair, impaired immune function, alterations in bone and blood vessel/connective tissue, alterations in cholesterol metabolism, and cognitive deficits
Gastrointestinal and Liver Physiology
